Summarized in Table 2, most clinical trials have primarily aimed to target Axl because of Axl’s known role in driving disease progression through expression on cancer cells, although some inhibitors also inhibit MerTK and other RTKs with lower affinity. The gene discussed is AXL; the disease is cancer.